(2S)-2-((S)- (3-(benzyloxy) phenyl) (6-methoxyquinolin-4-yl) methyl)-8-ethylquinuclidine (13a) ...... 13 (2S)-2-((S)-(4-(benzyloxy)phenyl) (6-methoxyquinolin-4-yl) methyl)-8-ethylquinuclidine (14a) ...... 14 (2S)-2-((R)-(2-(benzyloxy)naphthalen-3-yl) (6-methoxyquinolin-4-yl) .
Unless otherwise stated, all compounds were sourced commercially and used without further purification. Racemic azlactones were obtained following literature procedures from the corresponding commercially available racemic aminoacids and used immediately after purification. Methylene chloride was distilled from calcium hydride and stored under argon. Tetrahydrofuran was distilled over sodiumbenzophenone ketyl radical and stored under argon. Deuterated chloroform was distilled over sodium carbonate and stored under argon. All reactions were carried out under a protective argon atmosphere unless otherwise stated. Analytical CSP-HPLC was performed on a Daicel CHIRALPAK AD-H (4.6 mm x 25 cm) column.
Synthesis of the N-Protected amino acids:
Valine, Leucine, Methionine and L-Isoleucine with D-allo were sourced commercially. Cyclohexylglycine and 2-amino-3-ethylpentanoic acid were made via literature procedure. [1] The aminoacids were converted into their corresponding methyl esters using standard procedures. 
General procedure

Scheme 1: General procedure for the synthesis of N-protected amino acids
A round bottomed flask containing a solution of the appropriate amino acid methyl ester in CH 2 Cl 2 (0.45 M, 1.0 -1.2 eq.) was cooled to 0 °C, triethylamine or N,N-diisopropylethylamine (3.0 eq.) was added followed by 2,4,6-trichlorobenzoyl chloride (1.0 eq.) which was slowly added via syringe. After the addition was complete, the reaction was allowed to warm to room temperature and stirred for 16 h. The solution was then diluted further with CH 2 Cl 2 (ca. 100 mL) and washed with HCl (1 M, ca. 50 mL), NaOH (aq. 5% w/v, ca. 50 mL)) and brine (50 mL). The organic layer was dried over MgSO 4 , filtered, and solvent removed in vacuo. The resulting material was then placed in a round bottom flask with THF (10 mL/g) and NaOH (aq. 5% w/v, 10 mL/g) and stirred for a further 16 h. The THF was then carefully removed in vacuo and the solution acidified by addition of HCl (6 N) and extracted using CHCl 3 (3 x 80 mL). The organic layers were combined, dried over MgSO 4 , filtered and solvent removed in vacuo to to give the desired N-2,4,6-trichlorobenzoyl amino acid. Procedure A was followed using DL-valine methyl ester (1.18 g, 9.02 mmol), 2,4,6-trichlorobenzoyl chloride, (1.28 mL, 8.20 mmol) and triethylamine, to give 2,4,6 trichloro-N-benzoyl valine (2.46 4 (q), 163.3 (q), 135.6 (q), 133.3 (q), 132.6 (q), 127.7, 50.5, 40.8, 24.3, 22.4, 21.2. IR (solid, ): ν 3206, 3068, 2962, 1715, 1644, 1581, 1548, 1421, 1369, 1257, 1153, 1063, 933, 860, 820, 731 135.8 (q), 133.3 (q), 132.5 (q), 127.8, 51.3, 30.8, 29.3, 15.0. IR (solid, ): ν 3254, 3083, 2921, 1709, 1650, 1549, 1432, 1300, 1250, 1184, 1133, 956, 875, 851, 818, 802, 708, 679 127.7, 56.6, 40.5, 29.1, 27.5, 25.6, 25.5 (2C) . IR (solid, cm -1 ): ν 3269, 3077, 2929, 2855, 1713, 1649, 1547, 1449, 1368, 1305, 1270, 1137, 908, 856, 820, 806, 729, 698 6 (q), 127.8, 53.2, 44.2, 22.5, 22.3, 11.4, 11.3. IR (solid, ): ν 3283, 3088, 2095, 2878, 2480, 1721, 1615, 1582, 1547, 1459, 1368, 1344, 1208, 1138, 966, 857, 820, 804, 710 Procedure A was followed using L-isoleucine with D-allo-isoleucine methyl ester (2.00 g, 11.0 mmol), 2,4,6-trichlorobenzoyl chloride (1.42 mL, 9.1 mmol) and N,N-diisopropylethylamine (4.79 mL, 27.5 mmol) to give 48C ( 2, 128.8, 57.5, 55.9, 37.7, 37.4, 26.8, 25.6, 16.7, 16.0, 12.6, 12 2968, 1733, 1648, 1584, 1424, 1370, 1303, 1254, 1184, 872, 856, 821, 805, 729. 3 Conversion of N-2,4,6-trichlorobenzoyl amino acids to azlactones.
2,4,6-Trichloro-N-benzoyl valine (43a)
A round bottom flask was flushed with nitrogen, charged with a stirring bar and the appropriate N-2,4,6-trichlorobenzoyl amino acid (1.0 equiv.), fitted with a septum and CHCl 3 added via syringe. To this 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDCI) (1.1 equiv.) was added and stirring continued at room temperature for 1-4 h. The reaction mixture was then diluted with CH 2 Cl 2 washed twice with saturated NaHCO 3 solution at 0 o C, followed by washing with water. The organic layer was then dried over MgSO 4 , filtered and solvent removed in vacuo. The crude product was then filtered through a pad of silica gel using CH 2 Cl 2 as the eluent. The solvent was then removed in vacuo and the product dried as necessary under high vacuum and used inmediately without further purification.
Dynamic kinetic resolution of azlactones
4.1 General procedure B for the DKR of racemic azlactones. (Table 1) A 3 mL reaction vial containing a stirring bar was charged with the appropriate catalyst (0.02 mmol). The reaction vial was flushed with argon and fitted with a stopper. CH 2 Cl 2 (0.5 mL), Styrene (23L, 0.20 mmol) and allyl alcohol (27 L, 0.40 mmol) were added via syringe followed by the appropriate azlactone (0.20 mmol). The resulting reaction was stirred at room temperature for the time indicated in Table 1 . The solution was then poured directly onto a column of silica gel and the product purified by flash chromatography (2-10% EtOAc in hexane).
General procedure C for the DKR of racemic azlactones. (Table 2)
A 5 mL reaction vial containing a stirring bar was charged with the catalyst 16 (0.04 mmol). The reaction vial was flushed with argon and fitted with a stopper. The appropiate solvent (2-4 mL) and allyl alcohol (16 L, 0.24 mmol) were added via syringe followed by the appropriate N-protected Valine azlactone (0.20 mmol). The resulting reaction was stirred at 19 o C for the time indicated in Table   2 . The solution was filtered through a thin pad of silica gel to remove the catalyst, concentrated in vacuo and then purified by flash chromatography (49:1-9:1 hexane-EtOAc).
General procedure D for the DKR of racemic azlactones. (Scheme 1)
A 5 mL reaction vial containing a stirring bar was charged with the catalyst 16 (0.02-0.04 mmol). The reaction vial was flushed with argon and fitted with a stopper. CDCl 3 (2-4 mL) and allyl alcohol (16 L, 0.24 mmol) were added via syringe followed by the appropriate N-2,4,6-trichlorobenzoyl azlactone (0.20 mmol). The resulting reaction was stirred at 19 o C for the time indicated. The solution was filtered through a thin pad of silica gel to remove the catalyst, concentrated in vacuo and then purified by flash chromatography (49:1-9:1 hexane-EtOAc).
Sample preparation for CSP-HPLC analysis: Procedure for hydrogenolysis
The amide products following ring-opening of trichloroaryl azlactones are difficult to resolve using CSP-HPLC due to significant peak-tailing. To circumvent this difficulty the purified ring-opened products were reduced and dechlorinated by hydrogenolysis using the following procedure.
Scheme 2:Hydrogenation of 2,4,6-Trichloro-N-benzoyl aminoacid allyl esters
The compound (0.10 mmol) was placed in a round bottomed flask with EtOAc (1 mL), N,N-diisopropylethylamine (70 l, 0.40 mmol) and 10% Pd/C (10.6 mg, 10mol%). The flask was evacuated and filled with an atmosphere of H 2 (1 atm) for 4 h to afford the dechlorinated propyl ester upon purification by flash chromatography (2-10% EtOAc in hexane). Cl Cl Cl Procedure D was followed, stirring was continued for 72 h, to give the desired product (67 mg, 92%), 90% ee, as a white solid. M.p. 56-58 o C. CSP-HPLC analysis (using hydrogenolysis procedure): Chiralpak ADH (4.6 mm x 25 cm), hexane/IPA: 9/1, 1.0 mL min -1 , RT, UV detection at 220 nm, retention times: 7.8 min (major enantiomer) and 11.6 min (minor enantiomer). 1 Procedure D was followed, stirring was continued for 115 h, to give the desired product (73 mg, 96%), 83% ee, as a colourless oil. CSP-HPLC analysis (using hydrogenolysis procedure): Chiralpak ADH (4.6 mm x 25 cm), hexane/IPA: 9/1, 1.0 mL min -1 , RT, UV detection at 220 nm, retention times: 8.0 min (major enantiomer) and 12.2 min (minor enantiomer). 131.0, 127.7, 118.7, 65.7, 50.6, 41.3, 24.3, 22.4, 21.4 130.7, 127.8, 119.1, 66.1, 51.5, 31.3, 29.3, 15.0. IR (solid, ): ν 3247, 3081, 2917, 1731, 1644, 1582, 1548, 1427, 1296, 988, 819, 690 3H, H-7, H-9), 1.75-1.66 (m, 2H, H-8), 1.35-1.10 (m, 5H, H-7, H-8, H-9 ). 13 C NMR (100 MHz, CDCl 3 ): 170.4 (q), 162.9 (q), 135.5 (q), 133.9 (q), 132.6 (q), 130.97, 127.75, 118.76, 65.6, 56.7, 40.8, 29.1, 27.7, 25.6, 25.5. IR (solid, cm -1 ): ν 3255, 3079, 2928 130.97, 127.75, 118.76, 65.6, 56.7, 40.8, 29.1, 27.7, 25.6, 25.5. IR (solid, cm -1 ): ν 3255, 3079, , 2854 130.97, 127.75, 118.76, 65.6, 56.7, 40.8, 29.1, 27.7, 25.6, 25.5. IR (solid, cm -1 ): ν 3255, 3079, , 1736 130.97, 127.75, 118.76, 65.6, 56.7, 40.8, 29.1, 27.7, 25.6, 25.5. IR (solid, cm -1 ): ν 3255, 3079, , 1644 130.97, 127.75, 118.76, 65.6, 56.7, 40.8, 29.1, 27.7, 25.6, 25.5. IR (solid, cm -1 ): ν 3255, 3079, , 1580 130.97, 127.75, 118.76, 65.6, 56.7, 40.8, 29.1, 27.7, 25.6, 25.5. IR (solid, cm -1 ): ν 3255, 3079, , 1545 130.97, 127.75, 118.76, 65.6, 56.7, 40.8, 29.1, 27.7, 25.6, 25.5. IR (solid, cm -1 ): ν 3255, 3079, , 1449 130.97, 127.75, 118.76, 65.6, 56.7, 40.8, 29.1, 27.7, 25.6, 25.5. IR (solid, cm -1 ): ν 3255, 3079, , 1368 130.97, 127.75, 118.76, 65.6, 56.7, 40.8, 29.1, 27.7, 25.6, 25.5. IR (solid, cm -1 ): ν 3255, 3079, , 1252 130.97, 127.75, 118.76, 65.6, 56.7, 40.8, 29.1, 27.7, 25.6, 25.5. IR (solid, cm -1 ): ν 3255, 3079, , 1135 127.7, 118.7, 65.7, 53.5, 44.4, 22.5, 22.2, 11.4, 11.3. IR (solid, ): ν 3262, 3083, 2956, 2876, 1740, 1651, 1583, 1549, 1339, 1203, 1139, 984, 932, 850, 814, 699 2, 66.1, 55.6, 38.1, 26.3, 14.7, 11.8 ): ν 3273, 2925, 1740, 1648, 1581, 1547, 1459, 1368, 1298, 1246, 1185, 988, 930, 854, 820. The stereochemistry of the product was assigned by comparison with the NMR spectra recorded for the diasteromerically pure N- (2,4,6- 6 Synthesis of cinchona alkaloid catalysts 9-18:
2,4,6-trichloro-N-Benzoyl valine allyl ester (43)
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General procedure E for the formation of Grignard reagents
A suspension of freshly ground magnesium turnings in dry THF (1.05 eq., 0.25 M) under argon atmosphere was placed in a round bottomed flask. Aryl bromide (1.0 equiv.) and 1,2-dibromoethane (4-5 drops) were added and the mixture was heated under reflux until all magnesium dissolved (30-240 minutes). The resulting solution was used immediately. Phenylmagnesiumbromide solution in (2.0 M in THF) was purchased from Aldrich.
(8S,9S)-6'-methoxy-9-phenyl-cinchonan (9) [5] Electronic Supplementary Material (ESI) Phenylmagnesiumbromide in THF (3.0 mL, 2.0 M, 6.0 mmol) was added to a solution of 9-epichloroquinine (2.0 mmol, 686 mg) in THF (10 mL) and heated under reflux for 4 h. The solution was cooled and a saturated aqueous solution of NH 4 Cl (30 mL) was added. The resulting mixture was extracted with CH 2 Cl 2 (2 x 100 mL), the organic extracts were combined, dried over MgSO 4 A solution of 9-epi-chloroquinine (3.13 g, 9.12 mmol) in dry THF (36.5 mL) was added to a round bottom flask containing a solution of 1-((2-bromomagnesiumphenoxy)methyl)benzene (2.62 g, 9.12 mmol) in dry THF (36.5 mL) (prepared using general procedure E), and heated under reflux overnight under a protective argon atmosphere. The resulting solution was cooled and a saturated aqueous solution of NH 4 Cl (50 mL) was added. The resulting mixture was then extracted with CH 2 Cl 2 (2 x 200 mL), and the organic washings were combined, dried over MgSO 4 and solvent was removed under reduced pressure. The resulting residue was purified by flash chromatography (25:25:1 hexaneEtOAc-NEt 3 ) to give 10a (3.25 g, 88%) as an off-white solid. 5, 129.0, 128.4 (q), 128.1, 127.5, 127.2, 120.5, 120.3, 119.2, 114.9, 113.9, 111.8, 101.6, 76.8, 69.5, 59.1, 56.1, 55.1, 48.9, 40.5, 39.1, 28.3, 27.6. IR (solid, cm -1 ): ν 2928 5, 129.0, 128.4 (q), 128.1, 127.5, 127.2, 120.5, 120.3, 119.2, 114.9, 113.9, 111.8, 101.6, 76.8, 69.5, 59.1, 56.1, 55.1, 48.9, 40.5, 39.1, 28.3, 27.6. IR (solid, cm -1 ): ν , 2860 5, 129.0, 128.4 (q), 128.1, 127.5, 127.2, 120.5, 120.3, 119.2, 114.9, 113.9, 111.8, 101.6, 76.8, 69.5, 59.1, 56.1, 55.1, 48.9, 40.5, 39.1, 28.3, 27.6. IR (solid, cm -1 ): ν , 1620 5, 129.0, 128.4 (q), 128.1, 127.5, 127.2, 120.5, 120.3, 119.2, 114.9, 113.9, 111.8, 101.6, 76.8, 69.5, 59.1, 56.1, 55.1, 48.9, 40.5, 39.1, 28.3, 27.6. IR (solid, cm -1 ): ν , 1586 5, 129.0, 128.4 (q), 128.1, 127.5, 127.2, 120.5, 120.3, 119.2, 114.9, 113.9, 111.8, 101.6, 76.8, 69.5, 59.1, 56.1, 55.1, 48.9, 40.5, 39.1, 28.3, 27.6. IR (solid, cm -1 ): ν , 1507 5, 129.0, 128.4 (q), 128.1, 127.5, 127.2, 120.5, 120.3, 119.2, 114.9, 113.9, 111.8, 101.6, 76.8, 69.5, 59.1, 56.1, 55.1, 48.9, 40.5, 39.1, 28.3, 27.6. IR (solid, cm -1 ): ν , 1450 5, 129.0, 128.4 (q), 128.1, 127.5, 127.2, 120.5, 120.3, 119.2, 114.9, 113.9, 111.8, 101.6, 76.8, 69.5, 59.1, 56.1, 55.1, 48.9, 40.5, 39.1, 28.3, 27.6. IR (solid, cm -1 ): ν , 1225 5, 129.0, 128.4 (q), 128.1, 127.5, 127.2, 120.5, 120.3, 119.2, 114.9, 113.9, 111.8, 101.6, 76.8, 69.5, 59.1, 56.1, 55.1, 48.9, 40.5, 39.1, 28.3, 27.6. IR (solid, cm -1 ): ν , 1031 A solution of 9-epi-chloroquinine (2.60 g, 7.58 mmol) in dry THF (24.0 mL) was added to a round bottom flask containing a solution of 1-((2-bromomagnesium-4-methylphenoxy)methyl)benzene (2.29 g, 7.58 mmol) in dry THF (24.0 mL) (prepared using general procedure E), and heated under reflux overnight under a protective argon atmosphere. The resulting solution was cooled and a saturated aqueous solution of NH 4 Cl (30 mL) was added. The resulting mixture was then extracted with CH 2 Cl 2 (2 x 120 mL), and the organic washings were combined, dried over 6, 128.5, 128.1, 127.8, 127.5, 127.1, 120.8, 119.8, 113.8, 111.3, 102.0, 70.0, 59.7, 56.2, 54.8, 41.0, 39.3, 30.5, 28.2, 27.6, 20.4. IR (solid, ): ν 3031, 2927, 2855, 1621, 1502, 1324, 1234, 1036, 1020, 853, 797, 734, 699 6, 132.6 (q), 131.3, 128.8 (q), 127.7, 127.0, 126.5 (q), 120.3, 119.9, 114.7, 113.9, 102.3, 94.2, 59.2, 56.1, 55.5, 55.1, 40.8, 40.7 (br), 39.2, 27.8, 27.7, 27.4. IR (solid, ): ν 2935, 2859, 1621, 1586, 1508, 1473, 1232, 1153, 1075, 985, 851, 813, 681 . HRMS (ESI+): calcd. for [C 28 A solution of 9-epi-chloroquinine (1.71 g, 5.00 mmol) in dry THF (20 mL) was added to a round bottom flask containing a solution of 1-((3-bromomagnesiumphenoxy)methyl)benzene (1.58 g, 5.50 mmol) in dry THF (20 mL) (prepared using general procedure E), and heated under reflux for 4 h under a protective argon atmosphere. The resulting solution was cooled and a saturated aqueous solution of NH 4 Cl (25 mL) was added. The resulting mixture was extracted twice with CH 2 Cl 2 (2 x 150 mL), the organic extracts were combined, dried over MgSO 4 and solvent was removed under reduced pressure. The resulting material was purified by column chromatography (98:2 EtOAc-NH 3 (aq. 35% w/w)) to give 13a ( H NMR (600 MHz, CDCl 3 ): δ = 8.77 (d, J = 4.8, 1H, H-2'), 8.03 (d, J = 9.0, 1H, H-8'), 7.55 (br s, 1H, H-5'), 7.46-7.31 (m, 7H, H-8", H-9", H-10", H-3', H-7'), 7.21 (app. 
Preparation of 9-aryl-quinines (2S)-2-((R)-(2-(benzyloxy)phenyl)(6-methoxyquinolin-4-yl)methyl)-8-ethylquinuclidine (10a)
N
(2S)-2-((R)-(5-methyl-2-(methoxymethoxy)phenyl)(6-methoxyquinolin-4-yl)methyl)-5-vinylquinuclidine (11a)
(2S)-2-((R)-(5-chloro-2-(methoxymethoxy)phenyl)(6-methoxyquinolin-4-yl)methyl)-5-vinylquinuclidine (12a)
13
C NMR (100 MHz, CDCl 3 ): δ = 157.1 (q), 155.6 (q), 147.0, 144.1 (q), 141.7, 136.2 (q), 132.7, 131.1 (q), 130.1 (q), 129.0, 128.4(q), 128. 1, 127.6, 127.2, 120.8, 120.7, 119.9, 119.9, 113.8, 111.4, 102.1, 76.8, 69.9, 59.5, 56.0, 54.7, 40.9, 39.2, 27.9, 27.5, 27.5. IR (solid, ): ν 2946, 2831, 1619, 1581, 1485, 1249, 1224, 1023, 916, 837, 771, 750, 698 . HRMS (ES+): calcd. for: [C 33 A solution of 9-epi-chloroquinine (5.14 g, 15.0 mmol) in dry THF (60 mL) was added to a round bottom flask containing a solution of 1-((4-bromomagnesiumphenoxy)methyl)benzene (5.62 g, 19.5 mmol) in dry THF (60 mL) (prepared using general procedure E), and heated under reflux over night under a protective argon atmosphere. The resulting solution was cooled and a saturated aqueous solution of NH 4 Cl (100 mL) was added. The resulting mixture was extracted twice with CH 2 Cl 2 (2 x 200 mL), the organic extracts were combined, dried over MgSO 4 and solvent was removed under reduced pressure. The resulting material was purified by column chromatography (40:10:1 hexane-EtOAc-NEt 3 ) to give 14a ( 2, 146.6 (q), 144.4 (q), 141.5, 136.6 (q), 134.0 (q), 131.5, 128.4, 128.1, 127.5, 127.1, 120.5, 119.1, 114.4, 113.9, 101.7, 76.8 (q), 69.4, 59.2, 56.2, 55.1, 48.2, 40.5, 39.1, 28.4, 27.7, 27.6. IR (solid, cm -1 ): ν 2936 2, 146.6 (q), 144.4 (q), 141.5, 136.6 (q), 134.0 (q), 131.5, 128.4, 128.1, 127.5, 127.1, 120.5, 119.1, 114.4, 113.9, 101.7, 76.8 (q), 69.4, 59.2, 56.2, 55.1, 48.2, 40.5, 39.1, 28.4, 27.7, 27.6. IR (solid, cm -1 ): ν , 2202 2, 146.6 (q), 144.4 (q), 141.5, 136.6 (q), 134.0 (q), 131.5, 128.4, 128.1, 127.5, 127.1, 120.5, 119.1, 114.4, 113.9, 101.7, 76.8 (q), 69.4, 59.2, 56.2, 55.1, 48.2, 40.5, 39.1, 28.4, 27.7, 27.6. IR (solid, cm -1 ): ν , 1620 2, 146.6 (q), 144.4 (q), 141.5, 136.6 (q), 134.0 (q), 131.5, 128.4, 128.1, 127.5, 127.1, 120.5, 119.1, 114.4, 113.9, 101.7, 76.8 (q), 69.4, 59.2, 56.2, 55.1, 48.2, 40.5, 39.1, 28.4, 27.7, 27.6. IR (solid, cm -1 ): ν , 1586 2, 146.6 (q), 144.4 (q), 141.5, 136.6 (q), 134.0 (q), 131.5, 128.4, 128.1, 127.5, 127.1, 120.5, 119.1, 114.4, 113.9, 101.7, 76.8 (q), 69.4, 59.2, 56.2, 55.1, 48.2, 40.5, 39.1, 28.4, 27.7, 27.6. IR (solid, cm -1 ): ν , 1507 2, 146.6 (q), 144.4 (q), 141.5, 136.6 (q), 134.0 (q), 131.5, 128.4, 128.1, 127.5, 127.1, 120.5, 119.1, 114.4, 113.9, 101.7, 76.8 (q), 69.4, 59.2, 56.2, 55.1, 48.2, 40.5, 39.1, 28.4, 27.7, 27.6. IR (solid, cm -1 ): ν , 1471 2, 146.6 (q), 144.4 (q), 141.5, 136.6 (q), 134.0 (q), 131.5, 128.4, 128.1, 127.5, 127.1, 120.5, 119.1, 114.4, 113.9, 101.7, 76.8 (q), 69.4, 59.2, 56.2, 55.1, 48.2, 40.5, 39.1, 28.4, 27.7, 27.6. IR (solid, cm -1 ): ν , 1228 2, 146.6 (q), 144.4 (q), 141.5, 136.6 (q), 134.0 (q), 131.5, 128.4, 128.1, 127.5, 127.1, 120.5, 119.1, 114.4, 113.9, 101.7, 76.8 (q), 69.4, 59.2, 56.2, 55.1, 48.2, 40.5, 39.1, 28.4, 27.7, 27.6. IR (solid, cm -1 ): ν , 1027 Procedure as for 10a using a solution of 2-(benzyloxy)-3-bromomagnesiumnaphthalene (739 mg, 2.19 mmol) in THF (6.0 mL) and 9-epi-chloroquinine (500 mg, 1.46 mmol) in THF (6.0 mL) to give 15a (310 mg, 39%). 1 H NMR (400 MHz, CDCl 3 ): δ = 8.71 (d, J = 3.6, 1H, H-2'), 7.98 (d, J = 8.8, 1H, H-8'), 7.79-7.85 (br s, 1H, H-5'), 7.66 (d, J = 8.0, 1H, H-5"), 7.73 (d, J = 8.0, 1H, H-8"), 7.57 (d, J = 2.4, 1H, H-4"), 7.27-7.41 (m, 9H, H-3', H-7', H-6", H-7", H-10", H-11", H-12"), 7.23 (s, 1H, H-1"), 5.89-6.01 (m, 1H, H-10), 5.37-5.50 (br s, 1H, H-9), 5.05-5.27 (m, 4H, H-11, H-12, H-9"), 3.80-3.95 (br s, 1H, H-8), 3.66 (s, 3H, H-6'), 3.42-3.56 (br s, 1H, H-6a), 3.21-3.36 (br s, 1H, H-2b), 2.69-2.93 (m, 2H, H-6b, H-2a) , 2.27-2.41 (br s, 1H, H-3), 1.81-1.96 (br s, 1H, H-7b), 1.49-1.79 (m, 3H, H-4, H-5a, H-5b) , 0.96-1.10 (br s, 1H, H-7a).
C NMR (100 MHz, CDCl 3 ): δ = 157.1 (q), 154.5 (q), 147.0, 144.2 (q), 141.8, 135.8 (q) , 132.9 (q), 132.0 (q), 131. 1, 129.0 (q), 128.6 (q), 128.4 (q), 128.1, 127.8, 127.7, 127.5, 127.2, 125.9, 125.5, 123.3, 120.8, 120.1, 113.8, 106.14, 102.0, 76.8, 70.0, 59.7, 56.2, 54.7, 41.0, 39.3, 27.8, 27.6, 27.5. IR (solid, ): ν 2934, 2863, 1617, 1505, 1359, 1240, 1183, 1080, 1035, 915, 851, 739, 712 Procedure as for 10a using a solution of 2-(benzyloxy)-1-bromomagnesiumnaphthalene (1.68 g, 5.00 mmol) in THF (9.0 mL) and 9-epi-chloroquinine (686 mg, 2.00 mmol) in THF (9 mL) to give 16a (895 mg, 82% (br s, 0.24H, H-8"), 8.72 (d, J = 7.8, 0.76H, H-8"), 8.42 (d, J = 4.8, 0.76H, H-2'), 8.32 (d, J = 8.4, 0.24H, H-2'), 7.91 (d, J = 9.0, 1H, H-8'), 7.80-7.87 (m, 1H, H-5"), 7.69-7.79 (m, 1H, H-4"), 7.61-7.68 (m, 1H, H-7"), 7.35-7.55(m, 6H, H-6", H-10", H-11", H-12"), 7.28-7.34 (m, 1H, H-5'), 7.15-7.26 (m, 3H, H-3', H-3", H-7'), 6.06-6.17 (m, 0.24H, H-10), 5.85-6.01 (m, 0.76H, H-10), 5.54-5.63 (m, 0.24H, H-9), 5.37 (d, J = 11.4, 0.76H, H-9), 5.04-5.22 (m, 3H, H-9", H-12), 4.76-4.89 (m, 1H, H-11), 4.36-4.59 (m, 1H, H-8), 3.72 (s, 0.76H, H-6'), 3.29-3.57 (m, 3.28H, H-6a, H-6'), 3.03-3.23 (m, 1H, H-2b), 2.78-2.88 (m, 0.76H, H-3), 2.56-2.74 (m, 1H, H-3, H-6b), 2.41-2.52 (m, 0.24H, H-6b), 2.23-2.34 (m, 1H, H-2a), 2.08-2.16 (m, 1H, H-7a), 1.65-1.88 (m, 2H, H-4, H-5a), 1.47-1.60 (m, 0.76H, H-5b), 1.34-1.46 (m, 0.24H, H-5b), 1.13-1.22 (m, 0.24H, H-7b), 0.91-1.02 (m, 0.76H, H-7b 128.5, 127.3, 126.9, 123.5, 123.0, 122.8, 121.2, 114.6, 114.3, 102.2, 77.3, 70.6 (q), 56.8 (q), 56.4, 55.7, 44.6, 42.3, 40.1, 30.5, 28.3, 28.0. ( 13 C resonances associated with the major rotamer only) IR (solid, cm -1 ): ν 2924, 2860, 1620, 1508, 1453, 1430, 1237, 1088, 1024, 907, 803, 729, 696 4, 125.5, 124.5 (q), 123.8 (q), 123.4, 123.3 (q), 122.8, 122.3, 122.1 (q), 122.0, 120.6, 118.3, 116.1, 115.3, 112.9, 109.3, 98.3, 97.2, 64.6, 54.4, 50.9, 50.5, 50.4, 36.3, 34.4, 23.1, 22.7, 21.8. IR (solid, ): ν 2937, 2862, 1621, 1508, 1449, 1361, 1245, 1214, 1027, 908, 827, 727, 695 Procedure as for 10a using a solution of 2-(benzyloxy)-7-bromomagnesiumnaphthalene (1.01 g, 3.00 mmol) in THF (9.0 mL) and 9-epi-chloroquinine (686 mg, 2.00 mmol) in THF (9.0 mL) to give 18a 5, 127.0, 125.3, 123.6, 120.5, 118.3, 114.0, 106.7, 101.8, 85.0, 76.8, 69.5, 59.2, 56.1, 55.1, 49.3, 40.6, 39.0, 28.4, 27.6, 27.5. IR (solid, ): ν 2944, 2859, 1628, 1508, 1452, 1377, 1256, 1184, 1025, 1008, 827, 728 
General procedure F for the debenzylation of protected catalysts by hydrogenation
The benzylated catalyst precursors were placed in a round bottom flask with solvent and the flask was flushed with argon. 10% Pd/C (10 mol%) was added, the flask was evacuated, placed under an atmosphere of hydrogen gas at atmospheric pressure and stirred for 2-5 d. The flask was then evacuated and filled with an inert atmosphere. The mixture was filtered through a layer of celite with CH 2 Cl 2 and/or MeOH or EtOH as the eluens. The solvent was removed in vacuo to afford the product. -5'), 7.87 (d, J = 9.6, 1H, H-8'), 7.69 (d, J = 4.8, 1H, H-3') , 7.34 (dd, J = 2.4, 9.0, 1H, H-7'), 7.13 (d, J = 7.2, 1H, H-6"), 6 .87 (t, J = 7.2, 1H, H-4"), 6.76 (d, J = 8.4, 1H, H-3"), 6.60 (t, J = 7.2, 1H, H-5"), 5.17 (d, J = 11.2, 1H, H-9), 3.93 (s, 3H, H-6'), 3.71 (d, J = 7.8, 1H, H-8) 147.9, 144.3 (q), 131.4, 129.7 (q), 129.4 (q), 128.6, 126.8, 121.3, 120.3, 119.3, 115.2, 103.3, 59.3, 58.0, 55.8, 41.9, 41.1, 37.1, 29.2, 28.6, 27.3, 26.0, 12.4. IR (solid, cm -1 ): ν 2928 147.9, 144.3 (q), 131.4, 129.7 (q), 129.4 (q), 128.6, 126.8, 121.3, 120.3, 119.3, 115.2, 103.3, 59.3, 58.0, 55.8, 41.9, 41.1, 37.1, 29.2, 28.6, 27.3, 26.0, 12.4. IR (solid, cm -1 ): ν , 2969 147.9, 144.3 (q), 131.4, 129.7 (q), 129.4 (q), 128.6, 126.8, 121.3, 120.3, 119.3, 115.2, 103.3, 59.3, 58.0, 55.8, 41.9, 41.1, 37.1, 29.2, 28.6, 27.3, 26.0, 12.4. IR (solid, cm -1 ): ν , 1621 147.9, 144.3 (q), 131.4, 129.7 (q), 129.4 (q), 128.6, 126.8, 121.3, 120.3, 119.3, 115.2, 103.3, 59.3, 58.0, 55.8, 41.9, 41.1, 37.1, 29.2, 28.6, 27.3, 26.0, 12.4. IR (solid, cm -1 ): ν , 1586 147.9, 144.3 (q), 131.4, 129.7 (q), 129.4 (q), 128.6, 126.8, 121.3, 120.3, 119.3, 115.2, 103.3, 59.3, 58.0, 55.8, 41.9, 41.1, 37.1, 29.2, 28.6, 27.3, 26.0, 12.4. IR (solid, cm -1 ): ν , 1508 147.9, 144.3 (q), 131.4, 129.7 (q), 129.4 (q), 128.6, 126.8, 121.3, 120.3, 119.3, 115.2, 103.3, 59.3, 58.0, 55.8, 41.9, 41.1, 37.1, 29.2, 28.6, 27.3, 26.0, 12.4. IR (solid, cm -1 ): ν , 1454 147.9, 144.3 (q), 131.4, 129.7 (q), 129.4 (q), 128.6, 126.8, 121.3, 120.3, 119.3, 115.2, 103.3, 59.3, 58.0, 55.8, 41.9, 41.1, 37.1, 29.2, 28.6, 27.3, 26.0, 12.4. IR (solid, cm -1 ): ν , 1237 147.9, 144.3 (q), 131.4, 129.7 (q), 129.4 (q), 128.6, 126.8, 121.3, 120.3, 119.3, 115.2, 103.3, 59.3, 58.0, 55.8, 41.9, 41.1, 37.1, 29.2, 28.6, 27.3, 26.0, 12.4. IR (solid, cm -1 ): ν , 1029 
